Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
Provided By GlobeNewswire
Last update: Nov 5, 2025
Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety
Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels
Read more at globenewswire.com
